)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Kymera Therapeutics
Kymera Therapeutics (KYMR) investor relations material
Kymera Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic vision and company progress
Focused on delivering oral drugs with biologics-like activity for immunology and undrugged targets, celebrating 10 years of progress.
Raised nearly $1 billion in 2023, securing $1.6 billion in funding to support programs through 2029 and enable a fully integrated global company.
Collaborations with Sanofi and Gilead advance IRAK4, CDK2, and KT-485 programs, expanding the pipeline and leveraging partnerships.
Target selection strategy remains unchanged, focusing on oral therapies for immune-inflammatory diseases and historically undrugged pathways.
Building a team and capabilities to pioneer oral degraders with biologics-like efficacy and safety.
Market opportunity and patient impact
Addressing a large, underserved market of 160 million patients with immunological diseases, with only 3% accessing advanced therapies.
Oral drugs with biologics-like efficacy and safety could expand the $20–30 billion market to a much larger patient population.
KT-621 aims to be the first option for all patients with moderate to severe type 2 diseases, including children and adolescents.
Market analysis confirms patient preference for oral, rapid-acting, safe, and convenient therapies.
Company’s approach could transform treatment paradigms and improve access to advanced therapies.
Pipeline highlights and clinical development
KT-621, a first-in-class oral STAT6 degrader, is in two phase 2b studies for AD and asthma, with data expected in 2027 from about 500 patients.
KT-579, a first-in-class oral IRF5 degrader, completed IND-enabling studies and is set for Phase 1 trials in 2026.
Second-generation IRAK4 degrader (KT-485) and CDK2 molecular glue are advancing in collaboration with Sanofi and Gilead.
Strategy includes parallel phase 3 campaigns for multiple indications using selected doses from phase 2b studies.
Plans to disclose a new immunology program entering IND-enabling studies later this year.
KT-621 market expansion strategy
KT-621 data read-through to future degraders
Criteria for PROTAC vs. molecular glue selection?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kymera Therapeutics earnings date
Q4 202526 Feb, 2026
Kymera Therapeutics
Next Kymera Therapeutics earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapies. The company’s proprietary platform aims to design small-molecule drugs that selectively degrade disease-causing proteins, offering a novel approach to treating conditions that have been difficult to address with traditional therapies. Kymera Therapeutics is engaged in research and development across various therapeutic areas, including oncology, immunology, and inflammation. The company is headquartered in Watertown, United States, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage